CYB561D2 and central nervous system cancer: To explore the therapeutic potential of targeting CYB561D2 in gliomas, we used various in vitro assays to measure the effects of CYB561D2 knock-down in U251 and U87 cells infected with CYB561D2 shRNA or scramble at a MOI of 5.